Understand this story
On October 28, 2026, NeuroHawk Technology announced the completion of a RMB 700 million Series B financing round, jointly led by SDIC Jili, Shenzhen Capital Group, and Qinzhi Capital, with participation from SMIC Juyuan, Huangpu Investment, Cornerstone Capital, IDG Capital, and others. The funds will be used for multicenter clinical trials and registration approval of a "fully implanted, fully wireless, fully functional" brain-computer interface system, mass-production construction, and research and development of next-generation products. According to a 36Kr report, the system has completed 65 clinical trial cases and entered the Class III medical device registration clinical stage in July 2026, led by Huashan Hospital affiliated with Fudan University, with Professor Mao Ying's team serving as the principal investigators. Founder Tao Hu stated that the current data from a few dozen cases is still insufficient for the algorithm to transfer across different patients, and that several hundred or even several thousand cases need to be accumulated. According to a Securities Times report, the company plans a 14,300-square-meter super factory to achieve capacity of ten-thousand-unit scale.
AI-generated from public reports
Developments
1 confirmed developments
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Oct 28
Securities Times
NeuroXess Completes 700 Million Yuan Series B Financing to Advance Brain-Computer Interface Mass Production and BCI+AI R&D
NeuroXess announced on October 28 that it has completed a 700 million yuan Series B financing, jointly led by SDIC Jili, Shenzhen Capital Group, and Qinzhi Capital, with participation from SMIC Juyuan, Huangpu Investment, Cornerstone Capital, IDG Capital, and others. The funds will be used for multicenter clinical trials and registration approval of the "Three All" brain-computer interface system, mass production construction of the super factory, next-generation product R&D, and exploration of BCI+AI integration. The company said it has completed 65 clinical trials; its "Three All" system launched a GCP registration clinical trial on July 7, 2026, at Huashan Hospital affiliated with Fudan University, and it plans a 14,300-square-meter super factory to achieve capacity of tens of thousands of units.
English text is being prepared.Related discussion
English text is being prepared. joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
36Kr · AI
NeuroXess Completes 700 Million Yuan Series B Financing; Tri-All Brain-Computer Interface System Enters Registrational Clinical Trials
NeuroXess has completed a 700 million RMB Series B financing, jointly led by SDIC Jili, Shenzhen Capital Group, and Qinzhi Capital. The funds will be used for multicenter clinical trials and registration approval, mass-production construction, and next-generation product R&D for its "fully implanted, fully wireless, fully functional" brain-computer interface system. The system has completed 65 clinical trials, and in July this year entered the Class III medical device registrational clinical trial stage, led by Huashan Hospital affiliated with Fudan University, with Professor Mao Ying's team serving as the principal investigators. Founder Tao Hu said that the current dozens of cases of data are not yet sufficient for the algorithm to transfer across different patients, and hundreds or even thousands of cases need to be accumulated.
Heat trend for this story
- Current
- 18
- Period peak
- 19 Oct 28 12:00
- 24-hour change
- —
Move the pointer or select the chart to inspect hourly heat. Use the left and right arrow keys with a keyboard.